DRRA

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

[ad_1] Today, a brief rundown of news announced ahead of the J.P. Morgan Healthcare Conference, including licensing deals from AbbVie and Novartis, earnings announcements from Vertex Pharmaceuticals and Alnylam Pharmaceuticals, and a regulatory updates from Beam Therapeutics and Atara Biotherapeutics. AbbVie is paying Yantai, China-based RemeGen $650 million up front, and potentially more than $5…

Read More
Omidenepag isopropyl lowers IOP over 5 years

Omidenepag isopropyl lowers IOP over 5 years

[ad_1] January 12, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe We were unable to process your request. Please try again later. If you continue to…

Read More
Jubilant Biosys Announces New Facility in India

Jubilant Biosys Announces New Facility in India

[ad_1] On Jan. 12, 2026, Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, announced at the JP Morgan Healthcare Conference, which is being held in San Francisco from January 12–15, that it is opening a new discovery and preclinical facility at Noida in India (1). The new facility will double the contract…

Read More